Aromatase inhibitors and osteoporosis: Comment on the review by Felson and Cummings [5]

Arthritis and Rheumatism

Volumn 54, Issue 4, 2006, Pages 1355-1356

  Ranganathan, Prabha ^a   Armamento Villareal, Reina ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTRADIOL; EXEMESTANE; LETROZOLE; TAMOXIFEN;

BONE DENSITY; BREAST CANCER; CLINICAL TRIAL; CYP19 GENE; DRUG EFFECT; ENZYME ACTIVITY; ESTRADIOL BLOOD LEVEL; FRACTURE; GENE; GENETIC POLYMORPHISM; HORMONE SUBSTITUTION; HUMAN; LETTER; NUCLEIC ACID BASE SUBSTITUTION; OSTEOPOROSIS; PHARMACOGENETICS; PRIORITY JOURNAL; TANDEM REPEAT; TREATMENT RESPONSE; VERTEBRA FRACTURE;

AROMATASE; AROMATASE INHIBITORS; FEMALE; HUMANS; OSTEOPOROSIS;

EID: 33646350495     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21741     Document Type: Letter

References (11)

1. Felson DT, Cummings SR. Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation [review]. Arthritis Rheum 2005;52:2594-8.
2. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al, and the ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9.
3. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
4. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802.
5. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
6. Masi L. Becherini L, Gennari L, Amedei A, Colli E, Falchetti A, et al. Polymorphism of the aromatase gene in postmenopausal Italian women: distribution and correlation with bone mass and fracture risk. J Clin Endocrinol Metab 2001;86:2263-9.
7. Gennari L, Masi L, Merlotti D, Picariello L, Falchetti A, Tanini A, et al. A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. J Clin Endocrinol Metab 2004;89:2803-10.
8. Somner J, McLellan S, Cheung J, Mak YT, Frost ML, Knapp KM, et al. Polymorphisms in the P450 c17 (17-hydroxylase/17,20-Lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2004;89:344-51.
9. Zarrabeitia MT, Hernandez JL, Valero C, Zarrabeitia AL, Garcia-Unzueta M, Amado JA, et al. A common polymorphism in the 5′-untranslated region of the aromatase gene influences bone mass and fracture risk. Eur J Endocrinol 2004;150:699-704.
10. Tofteng CL, Kindmark A, Brandstrom H, Abrahamsen B, Petersen S, Stiger F, et al. Polymorphisms in the CYP19 and AR genes: relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: the Danish Osteoporosis Prevention Study. Calcif Tissue Int 2004;74:25-34.
11. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-91.